Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Axsome Therapeutics, Inc.

Biotech SG&A Expenses: A Decade of Growth and Strategy

__timestampAxsome Therapeutics, Inc.Intra-Cellular Therapies, Inc.
Wednesday, January 1, 2014139283010337679
Thursday, January 1, 2015241928918187286
Friday, January 1, 2016634364824758063
Sunday, January 1, 2017720669123666957
Monday, January 1, 2018935152230099855
Tuesday, January 1, 20191359803064947625
Wednesday, January 1, 202028896749186363444
Friday, January 1, 202166646205272611040
Saturday, January 1, 2022159253661358782000
Sunday, January 1, 2023323123000409864000
Monday, January 1, 2024411359000
Loading chart...

Cracking the code

Navigating SG&A Expenses: A Tale of Two Biotechs

In the competitive landscape of biotechnology, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Axsome Therapeutics, Inc. over the past decade. From 2014 to 2023, Intra-Cellular Therapies saw a staggering 3,860% increase in SG&A expenses, peaking at approximately $410 million in 2023. Meanwhile, Axsome Therapeutics experienced a remarkable 23,000% surge, reaching around $323 million in the same year.

This trend highlights the aggressive expansion and operational scaling these companies have undertaken. Notably, the sharp rise in expenses from 2020 onwards reflects strategic investments in marketing and administrative capabilities, essential for sustaining growth in a rapidly evolving market. As these biotechs continue to innovate, understanding their cost structures offers valuable insights into their financial health and strategic priorities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025